Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(0.52)
# 4,128
Out of 4,994 analysts
136
Total ratings
36.8%
Success rate
-4.7%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Upgraded: Buy | $22 | $21.05 | +4.51% | 2 | Sep 22, 2026 | |
| MNKD MannKind | Reiterated: Buy | $8 | $3.49 | +129.23% | 6 | Sep 10, 2026 | |
| TENX Tenax Therapeutics | Reiterated: Buy | $35 | $1.94 | +1,704.12% | 4 | Sep 9, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $85 → $86 | $63.37 | +35.71% | 19 | Sep 1, 2026 | |
| BRVE Braveheart Bio | Initiated Coverage: Buy | $40 | $23.61 | +69.42% | 1 | Aug 31, 2026 | |
| MIST Milestone Pharmaceuticals | Initiated Coverage: Buy | $3 | $0.921 | +225.73% | 1 | Aug 20, 2026 | |
| QNCX Quince Therapeutics | Reiterated: Buy | $80 → $70 | $31.35 | +123.29% | 2 | Aug 17, 2026 | |
| INSM Insmed | Reiterated: Buy | $235 | $120.82 | +94.50% | 5 | Aug 6, 2026 | |
| VNDA Vanda Pharmaceuticals | Reiterated: Buy | $11 | $5.21 | +111.13% | 6 | Aug 6, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $1.22 | +229.22% | 1 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.31 | +73.16% | 2 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $23.24 | +115.15% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $12 | $2.94 | +308.16% | 5 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.69 | - | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $525 → $625 | $497.59 | +25.61% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $450 → $400 | $251.65 | +58.95% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $514.99 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $405 → $340 | $410.24 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $55 | $62.25 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $70 → $80 | $152.67 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $795 → $925 | $803.90 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $10 | $16.67 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $59.03 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $4.13 | n/a | 4 | Mar 20, 2023 |
Omeros
Sep 22, 2026
Upgraded: Buy
Price Target: $22
Current: $21.05
Upside: +4.51%
MannKind
Sep 10, 2026
Reiterated: Buy
Price Target: $8
Current: $3.49
Upside: +129.23%
Tenax Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $35
Current: $1.94
Upside: +1,704.12%
BioMarin Pharmaceutical
Sep 1, 2026
Reiterated: Buy
Price Target: $85 → $86
Current: $63.37
Upside: +35.71%
Braveheart Bio
Aug 31, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $23.61
Upside: +69.42%
Milestone Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $3
Current: $0.921
Upside: +225.73%
Quince Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $80 → $70
Current: $31.35
Upside: +123.29%
Insmed
Aug 6, 2026
Reiterated: Buy
Price Target: $235
Current: $120.82
Upside: +94.50%
Vanda Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $11
Current: $5.21
Upside: +111.13%
Connect Biopharma Holdings
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $1.22
Upside: +229.22%
May 18, 2026
Reiterated: Buy
Price Target: $4
Current: $2.31
Upside: +73.16%
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $23.24
Upside: +115.15%
Mar 20, 2026
Reiterated: Buy
Price Target: $10 → $12
Current: $2.94
Upside: +308.16%
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $11.69
Upside: -
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $525 → $625
Current: $497.59
Upside: +25.61%
Feb 12, 2026
Reiterated: Hold
Price Target: $450 → $400
Current: $251.65
Upside: +58.95%
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $514.99
Upside: n/a
Feb 5, 2025
Reiterated: Buy
Price Target: $405 → $340
Current: $410.24
Upside: n/a
Feb 4, 2025
Reiterated: Hold
Price Target: $52 → $55
Current: $62.25
Upside: n/a
Nov 6, 2024
Reiterated: Hold
Price Target: $70 → $80
Current: $152.67
Upside: n/a
Apr 17, 2024
Reiterated: Hold
Price Target: $795 → $925
Current: $803.90
Upside: n/a
Feb 23, 2024
Reiterated: Buy
Price Target: $15 → $10
Current: $16.67
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $59.03
Upside: n/a
Mar 20, 2023
Reiterated: Hold
Price Target: $3
Current: $4.13
Upside: n/a